Amplifi Vascular Announces Successful First-in-Human Study Results, Closes $6.8M Series A, and Receives FDA IDE Approval
October 9, 2025
ST. LOUIS, Oct. 9, 2025 /PRNewswire/ — Amplifi Vascular, developer of the first-of-its-kind Vein Dilation System designed to increase eligibility, improve creation and early maturation of arteriovenous fistulas (AVFs) for hemodialysis, today announced three major milestones: positive first-in-human (FIH) study results, the close of a $6.9 million Series A financing, and U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE).
